Eric Falls, DPM
Foot & Ankle Surgery · Vestavia Hls, ALNPI 1023180882
Payments from drug & device makers
What this record shows
12 manufacturers reported payments, led by Stryker at 51.6% of the total. Reporting peaked in 2023 at $368 and has fallen 93.5% since, to $24 in 2025. That places this record below the midpoint for foot & ankle surgery clinicians in AL, where the typical reported total is $4,589.
Across 16 payments — averaging $38.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$321
- Amgen$58
- Organogenesis Inc.$47
- Paratek Pharmaceuticals, Inc.$33
- Abbott$25
- Bioventus LLC$24
- plus $114 from 6 others
What the payments were for
- Food & beverage$34255%
- Education$28045%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 2 | $321 |
| Amgen | 2 | $58 |
| Organogenesis Inc. | 2 | $47 |
| Paratek Pharmaceuticals, Inc. | 2 | $33 |
| Abbott | 1 | $25 |
| Bioventus LLC | 1 | $24 |
| Averitas Pharma Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $20 |
| Boston Scientific | 1 | $18 |
| Orthofix Medical, Inc. | 1 | $18 |
| Fidia Pharma USA Inc. | 1 | $17 |
| Medtronic | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROPHECY$280
How this compares
$622 in reported general payments places this provider in the 10th percentile of 40 foot & ankle surgery providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort | 61 | $3,205 |
| Diclofenac Sodium | 35 | $1,642 |
| Pregabalin | 64 | $1,516 |
| Oxaprozin | 17 | $1,430 |
| Cephalexin | 68 | $1,259 |
| Econazole Nitrate | 22 | $907 |
| Terbinafine Hcl | 41 | $798 |
| Mupirocin | 59 | $534 |
| Ketoconazole | 13 | $430 |
| Doxycycline Hyclate | 31 | $360 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 14 | $314 |
| Ammonium Lactate | 22 | $272 |
| Gabapentin | 11 | $214 |
| Celecoxib | 12 | $153 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 15 | $51 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Vestavia Hls
- Norman WaldropBirmingham$3.6M
- Justin DaigreDecatur$372K
- John KirchnerHoover$84K
- Jefferson SabatiniHuntsville$56K
- Matthew DeorioHuntsville$49K
- Patricia AnteroTuscaloosa$35K
- Ashish ShahBirmingham$28K
- Alfred RicciMontgomery$25K
- Swapnil SinghBirmingham$14K
- Derek KlavasMobile$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.